IL6 and lymphoma: EDU assay was used to strengthen the data; the ratio of proliferating cells showed that the cell proliferation of lymphoma cells was lower in UCMSCs-Tandab(IL-6/CD20) groups compared with other groups (UCMSCs-Vector, UCMSCs, rituximab, tocilizumab and combined treatment of rituximab and tocilizumab).